SS-31 (Elamipretide): The Mitochondria-Targeting Peptide Now FDA-Approved
SS-31 is a groundbreaking peptide that goes directly to the source of cellular energy – your mitochondria. In September 2025, it became the first mitochondrial therapy approved by the FDA, marking a major milestone in the treatment of energy-related disorders.
What Is SS-31?
SS-31, also known as Elamipretide (and previously MTP-131 or Bendavia), is a synthetic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH₂. Developed by Dr. Hazel Szeto at Cornell University, it’s designed to selectively target and accumulate in the inner mitochondrial membrane.
What makes SS-31 unique: it binds directly to cardiolipin, a phospholipid essential for mitochondrial structure and function. By stabilizing cardiolipin, SS-31 helps mitochondria work more efficiently.
How SS-31 Works
Its mechanism centers on protecting and optimizing mitochondrial function:
Cardiolipin Stabilization
Cardiolipin is critical for the structure of mitochondrial cristae (the inner folds where energy production happens). SS-31 binds to cardiolipin and stabilizes it, improving membrane integrity and electron transport chain efficiency.
Enhanced ATP Production
By optimizing electron flow, this peptide increases ATP synthesis – the energy currency your cells need to function.
Reduced Oxidative Stress
Elamipretide works as an antioxidant at the source – right where reactive oxygen species (ROS) are produced – rather than just scavenging them after the fact.
Improved ADP Sensitivity
Research shows SS-31 binds directly to the adenine nucleotide translocator (ANT), improving the transport of ADP into mitochondria for ATP production.
FDA Approval: A Historic Milestone
In September 2025, the FDA granted accelerated approval for Forzinity (elamipretide injection) as the first treatment for Barth syndrome – a rare mitochondrial disorder affecting fewer than 300 individuals.
Clinical trial results showed:
- Significant improvement in 6-Minute Walk Test performance
- Better heart function and cardiac physiology
- Improved symptom scores after 48 weeks of treatment
One patient reported being able to walk a quarter mile to baseball games without taking breaks – something impossible before treatment.
What the Research Shows About SS-31
Aging & Exercise Tolerance
In aged mice, 8 weeks of SS-31 treatment:
- Reversed age-related decline in ATP production
- Improved coupling of oxidative phosphorylation
- Increased exercise tolerance and muscle endurance
- Restored redox balance across the muscle proteome
Importantly, these benefits came without increasing mitochondrial content – Elamipretide improved mitochondrial quality, not quantity.
Heart Function
In dogs with advanced heart failure, chronic elamipretide therapy:
- Improved left ventricular function
- Increased ejection fraction and cardiac output
- Normalized heart failure biomarkers
- Reversed mitochondrial dysfunction
Kidney Protection
Studies show SS-31:
- Reduces kidney injury in ischemia-reperfusion models
- Protects mitochondrial structure in diabetic nephropathy
- Accelerates ATP recovery in renal tissue
Neurodegenerative Potential
Given mitochondrial dysfunction’s role in Alzheimer’s and Parkinson’s, Elamipretide is being studied for neuroprotective applications.
Why Cardiolipin Matters
Cardiolipin is found almost exclusively in the inner mitochondrial membrane. It:
- Organizes the electron transport chain complexes
- Maintains cristae structure
- Enables efficient ATP synthesis
- Declines with age and disease
When cardiolipin is damaged or depleted, mitochondrial function suffers. SS-31 addresses this directly.
The Bottom Line on SS-31
SS-31 represents a fundamentally new approach to cellular health – targeting the root of energy production rather than just symptoms. Its FDA approval for Barth syndrome validates decades of research and opens the door for potential applications in heart disease, aging, kidney protection, and neurodegenerative conditions.
Disclaimer: This article is for educational purposes only. NexGen Peptides products are intended for laboratory research use only. Not for human consumption. SS-31 (Elamipretide) is FDA-approved only for Barth syndrome; other uses remain investigational.
References:
- Siegel MP, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress. Free Radic Biol Med. 2013.
- Sabbah HN, et al. Chronic therapy with elamipretide in dogs with advanced heart failure. Circ Heart Fail. 2016.
- FDA. Accelerated Approval of Forzinity (Elamipretide) for Barth Syndrome. September 2025.